Safety and Adverse Events Among Long-term Care Residents Receiving a Third COVID-19 mRNA Vaccine Booster Dose in Quebec | Geriatrics | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Safety and Adverse Events Among Long-term Care Residents Receiving a Third COVID-19 mRNA Vaccine Booster Dose in Quebec

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME

Booster doses of mRNA COVID-19 vaccines are administered worldwide to enhance antibody levels and immunity against Delta, Omicron, and emerging variants. Data on adverse events show a favorable safety profile, with similar reactogenicity for second and third doses. However, safety in older adults in long-term care (LTC) settings has not been well described.1,2 We examined adverse events following mRNA booster vaccination in LTC residents within the context of factors unique to the province of Quebec that may increase reactogenicity: extended interval between doses 1 and 2,3 heterologous vaccination, full dose mRNA-1273 (100 µg) booster,4 and high prevalence of previous COVID-19 infection.5

Sign in to take quiz and track your certificates

Buy This Activity

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: June 6, 2022.

Published: July 21, 2022. doi:10.1001/jamanetworkopen.2022.23401

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Zhang XS et al. JAMA Network Open.

Corresponding Author: Quoc Dinh Nguyen, MD, MPH, PhD, Division of Geriatrics, Department of Medicine, Centre hospitalier de l’Université de Montréal, 1000 rue Saint-Denis, Montreal, QC H2X 0C1, Canada (quoc.dinh.nguyen@umontreal.ca).

Author Contributions: Dr Nguyen had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Zhang, Moreau, Nguyen.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Nguyen.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Nguyen.

Administrative, technical, or material support: Zhang, Moreau, Cruz-Santiago, Nguyen.

Supervision: Zhang, Moreau, Nguyen.

Conflict of Interest Disclosures: None reported.

References
1.
Barda  N , Dagan  N , Cohen  C ,  et al.  Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.   Lancet. 2021;398(10316):2093-2100. doi:10.1016/S0140-6736(21)02249-2PubMedGoogle ScholarCrossref
2.
Hause  AM , Baggs  J , Marquez  P ,  et al.  Safety monitoring of COVID-19 vaccine booster doses among adults — United States, September 22, 2021–February 6, 2022.   MMWR Morb Mortal Wkly Rep. 2022;71(7):249-254. doi:10.15585/mmwr.mm7107e1PubMedGoogle ScholarCrossref
3.
Grunau  B , Goldfarb  DM , Asamoah-Boaheng  M ,  et al.  Immunogenicity of extended mRNA SARS-CoV-2 vaccine dosing intervals.   JAMA. 2022;327(3):279-281. doi:10.1001/jama.2021.21921PubMedGoogle ScholarCrossref
4.
Atmar  RL , Lyke  KE , Deming  ME ,  et al; DMID 21-0012 Study Group.  Homologous and heterologous Covid-19 booster vaccinations.   N Engl J Med. 2022;386(11):1046-1057. Published online January 26, 2022. doi:10.1056/NEJMoa2116414PubMedGoogle ScholarCrossref
5.
Wang  Z , Muecksch  F , Schaefer-Babajew  D ,  et al.  Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection.   Nature. 2021;595(7867):426-431. doi:10.1038/s41586-021-03696-9PubMedGoogle ScholarCrossref
6.
Munro  APS , Janani  L , Cornelius  V ,  et al; COV-BOOST study group.  Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.   Lancet. 2021;398(10318):2258-2276. doi:10.1016/S0140-6736(21)02717-3PubMedGoogle ScholarCrossref
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close